このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Newron Pharmaceuticals 将来の成長

Future 基準チェック /66

Newron Pharmaceuticals利益と収益がそれぞれ年間51.2%と39.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に143% 51.1%なると予測されています。

主要情報

51.2%

収益成長率

51.1%

EPS成長率

Pharmaceuticals 収益成長	11.5%
収益成長率	39.2%
将来の株主資本利益率	143.0%
アナリストカバレッジ	Low
最終更新日	27 Jun 2024

今後の成長に関する最新情報

Recent updates

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Apr 11

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

Nov 06

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Apr 06

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Apr 01

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

Feb 25

業績と収益の成長予測

SWX:NWRN - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	43	23	31	31	2
12/31/2025	27	5	14	14	3
12/31/2024	37	15	29	28	3
12/31/2023	9	-16	-10	-10	N/A
9/30/2023	9	-16	-11	-11	N/A
6/30/2023	9	-16	-11	-11	N/A
3/31/2023	7	-17	-11	-11	N/A
12/31/2022	6	-17	-11	-11	N/A
9/30/2022	6	-16	-10	-10	N/A
6/30/2022	6	-14	-8	-8	N/A
3/31/2022	6	-15	-10	-10	N/A
12/31/2021	6	-15	-11	-11	N/A
9/30/2021	6	-17	-14	-14	N/A
6/30/2021	5	-20	-17	-17	N/A
3/31/2021	5	-20	-16	-16	N/A
12/31/2020	5	-21	-16	-16	N/A
9/30/2020	6	-19	-15	-15	N/A
6/30/2020	7	-17	-14	-14	N/A
3/31/2020	7	-18	-18	-18	N/A
12/31/2019	7	-20	-22	-22	N/A
9/30/2019	6	-21	-22	-22	N/A
6/30/2019	4	-21	-21	-21	N/A
3/31/2019	4	-18	-19	-19	N/A
12/31/2018	4	-15	-16	-16	N/A
9/30/2018	4	-15	-16	-16	N/A
6/30/2018	4	-14	-16	-16	N/A
3/31/2018	9	-10	-12	-12	N/A
12/31/2017	13	-5	-8	-8	N/A
9/30/2017	14	-5	N/A	-10	N/A
6/30/2017	15	-5	N/A	-12	N/A
3/31/2017	11	-10	N/A	-16	N/A
12/31/2016	7	-15	N/A	-20	N/A
9/30/2016	6	-20	N/A	-18	N/A
6/30/2016	4	-25	N/A	-17	N/A
3/31/2016	3	-24	N/A	-15	N/A
12/31/2015	2	-23	N/A	-13	N/A
9/30/2015	2	-18	N/A	-12	N/A
6/30/2015	2	-12	N/A	-11	N/A
3/31/2015	2	-11	N/A	-10	N/A
12/31/2014	2	-10	N/A	-10	N/A
9/30/2014	2	-10	N/A	-9	N/A
6/30/2014	3	-9	N/A	-8	N/A
3/31/2014	3	-8	N/A	-9	N/A
12/31/2013	4	-7	N/A	-11	N/A
9/30/2013	4	-7	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NWRNは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.2% ) よりも高い成長率であると考えられます。

収益対市場: NWRN今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: NWRN今後 3 年以内に収益を上げることが予想されます。

収益対市場: NWRNの収益 ( 39.2% ) Swiss市場 ( 4.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: NWRNの収益 ( 39.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NWRNの自己資本利益率は、3年後には非常に高くなると予測されています ( 143 %)。

Newron Pharmaceuticals 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 19%

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Forecast breakeven date moved forward to 2023

Recent updates

Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Forecast breakeven date pushed back to 2026

Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being

Consensus revenue estimates fall by 19%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Forecast breakeven date pushed back to 2025

Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia (TRS)

Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide

Newron Pharmaceuticals S.p.A. to Report Fiscal Year 2023 Results on Mar 19, 2024

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2023

Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor

New minor risk - Market cap size

Forecast breakeven date moved forward to 2023

Full year 2022 earnings released: €0.98 loss per share (vs €0.83 loss in FY 2021)

Newron Reports Striking One-Year Interim Efficacy Results from Its Phase Ii Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A. Announces Striking Six-Month Interim Results from Its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 18, 2023

Insufficient new directors

First half 2022 earnings released: €0.48 loss per share (vs €0.51 loss in 1H 2021)

Newron Pharmaceuticals S.P.A. Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia (Trs) At the 33Rd Cinp Hybrid World Congress of Neuropsychopharmacology

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt

First half 2021 earnings released: €0.51 loss per share (vs €0.59 loss in 1H 2020)

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA Filings for Xadago® (safinamide) in the USA

Newron Pharmaceuticals S.p.A. Announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA

Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package

Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2020 earnings released: €1.18 loss per share (vs €1.13 loss in FY 2019)

Newron Pharmaceuticals S.p.A., Annual General Meeting, Apr 13, 2021

Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Disease Patients

New 90-day high: CHF2.99

A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns

New 90-day high: CHF2.95

Newron Pharmaceuticals Completes Enrollment of Explanatory Safety and Efficacy Study with Evenamide in Schizophrenia Patients

New 90-day high: CHF2.25

New 90-day high: CHF2.11

Analysts lower EPS estimates to -€1.17

First half earnings released

New 90-day low - CHF1.55

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘